Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | NPY1R | P25929 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24153499 | 0.95 | HTR1A (0.39) | HTR1ANPY1R | |
| SCHEMBL24153475 | 0.92 | KMT2A (0.38) | HTR1ANPY1R | |
| SCHEMBL24153493 | 0.91 | HDAC6 (0.38) | HDAC6 | |
| SCHEMBL24153484 | 0.89 | NPY1R (0.37) | HTR1AHDAC6NPY1R | |
| SCHEMBL24153512 | 0.89 | — | — | |
| SCHEMBL24153600 | 0.89 | MCHR1 (0.37) | HTR1ANPY1R | |
| SCHEMBL24938892 | 0.89 | NPY1R (0.41) | HTR1ANPY1R | |
| SCHEMBL24939891 | 0.89 | LMNA (0.42) | HTR1ANPY1R | |
| SCHEMBL24939892 | 0.88 | LMNA (0.38) | HTR1ANPY1R | |
| SCHEMBL24153500 | 0.88 | HTR1A (0.39) | HTR1ANPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019094-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME | HOLOSMEDIC (KR) | 2023-01-19 | — | — | US | disclosed |
| WO-2021261969-A1 | PREPARATION METHOD FOR NOVEL COMPOUND | 홀로스메딕 주식회사 | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019094-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCC1 | HTR1A 4854/4885HDAC6 14/4885NPY1R 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.